BlackRock Fund Advisors recently announced the acquisition of new stake in Enanta Pharmaceuticals Inc. (NASDAQ:ENTA). The institutional investor has increased its shareholding in the Healthcare company by 3.53% to 3.16 million shares with purchase of 0.11 million shares. This fresh investment now brings its stake to 15.17% valued currently at $146.77 million. In addition, Armistice Capital LLC raised its holdings by 2000.0 to 2.07 million shares. And Northern Trust Investments, Inc. has lifted its position by 3.52% or 32441.0 shares – to 0.95 million shares.
With over 0.22 million Enanta Pharmaceuticals Inc. (ENTA) shares trading Friday and a closing price of $50.28 on the day, the dollar volume was approximately $11.22 million. The shares have shown a positive half year performance of 2.07% and its price on 01/20/23 lost nearly -0.24%. Currently, there are 20.76M common shares owned by the public and among those 19.38M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Insiders at the company have transacted a total of 65 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 36 of these insider trades were purchases, accounting for 391,484 shares. Insider sales of the common stock occurred on 29 occasions, with total insider shares sold totaling 173,202 shares.
The top 3 mutual fund holders in Enanta Pharmaceuticals Inc. are iShares Core S&P Small Cap ETF, SPDR S&P Biotech ETF, and Vanguard Total Stock Market Index. iShares Core S&P Small Cap ETF owns 1.44 million shares of the company’s stock, all valued at over $67.04 million. The company sold 1088.0 shares recently to bring their total holdings to about 6.93% of the shares outstanding. SPDR S&P Biotech ETF bought 3312.0 shares to see its total holdings expand to 0.82 million shares valued at over $38.06 million and representing 3.93% of the shares outstanding. Vanguard Total Stock Market Index now owns shares totaling to 2.83% of the shares outstanding.
Shares of Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) opened at $51.18, up $0.78 from a prior closing price of $50.40. However, the script later moved the day high at 51.18, down -0.24%. The company’s stock has a 5-day price change of -4.30% and 8.04% over the past three months. ENTA shares are trading 8.08% year to date (YTD), with the 12-month market performance down to -14.36% lower. It has a 12-month low price of $37.59 and touched a high of $79.50 over the same period. ENTA has an average intraday trading volume of 169.05K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.97%, 10.44%, and -4.14% respectively.
Institutional ownership of Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) shares accounts for 95.90% of the company’s 20.76M shares outstanding. Mutual fund holders own 41.23%, while other institutional holders and individual stakeholders account for 53.50% and 34.74% respectively.
It has a market capitalization of $1.05B and a beta (3y monthly) value of 0.36. The earnings-per-share (ttm) stands at -$5.91. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.82% over the week and 6.03% over the month.
Analysts forecast that Enanta Pharmaceuticals Inc. (ENTA) will achieve an EPS of -$1.35 for the current quarter, -$1.34 for the next quarter and -$3.81 for 2023. The lowest estimate earnings-per-share for the quarter is -$1.61 while analysts give the company a high EPS estimate of -$1.1. Comparatively, EPS for the current quarter was -$1.22 a year ago. Earnings per share for the fiscal year are expected to decrease by -50.90%, and 58.70% over the next financial year.
Looking at the support for the ENTA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 09, 2022, with the firm’s price target at $56. Evercore ISI coverage for the Enanta Pharmaceuticals Inc. (ENTA) stock in a research note released on July 06, 2022 offered a Outperform rating with a price target of $62. Evercore ISI was of a view on June 01, 2022 that the stock is In-line, while Jefferies gave the stock Buy rating on October 07, 2021, issuing a price target of $95. SVB Leerink on their part issued Mkt Perform rating on September 09, 2021.
